90 related articles for article (PubMed ID: 17603723)
21. Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.
Di Bacco A; Keeshan K; McKenna SL; Cotter TG
Oncologist; 2000; 5(5):405-15. PubMed ID: 11040277
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
23. Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.
Qian J; Wang YL; Lin J; Yao DM; Xu WR; Wu CY
Eur J Haematol; 2009 Feb; 82(2):119-23. PubMed ID: 19018866
[TBL] [Abstract][Full Text] [Related]
24. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
25. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
26. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
27. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.
Maia V; Sanz M; Gutierrez-Berzal J; de Luis A; Gutierrez-Uzquiza A; Porras A; Guerrero C
Cell Signal; 2009 Jul; 21(7):1229-35. PubMed ID: 19324082
[TBL] [Abstract][Full Text] [Related]
28. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
Zhang SJ; Shi JY; Li JY
Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
[TBL] [Abstract][Full Text] [Related]
29. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
30. Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
Scrideli CA; de Oliveira FM; Brassesco MS; de Paula Queiroz R; Bernardes JE; Valera ET; Tone LG
Leuk Res; 2009 Mar; 33(3):495-9. PubMed ID: 18495245
[TBL] [Abstract][Full Text] [Related]
31. A chronic myeloid leukemia-like syndrome case with del (12) (p12) in a Li-Fraumeni syndrome family.
Guran S; Beyan C; Nevruz O; Yakicier C; Tunca Y
Clin Lab Haematol; 2005 Apr; 27(2):135-8. PubMed ID: 15784129
[TBL] [Abstract][Full Text] [Related]
32. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
33. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
34. Proteasome proteolytic profile is linked to Bcr-Abl expression.
Crawford LJ; Windrum P; Magill L; Melo JV; McCallum L; McMullin MF; Ovaa H; Walker B; Irvine AE
Exp Hematol; 2009 Mar; 37(3):357-66. PubMed ID: 19157685
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of apoptotic cells and immunohistochemical detection of FAS, FAS-L, Bcl-2, Bax, p53 and c-Myc in the skin of patients with chronic venous leg ulcers.
Heising S; Giebel J; Ostrowitzki AL; Riedel F; Haase H; Sippel K; Jünger M
Int J Mol Med; 2008 Oct; 22(4):497-505. PubMed ID: 18813857
[TBL] [Abstract][Full Text] [Related]
36. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
37. Novel morpholin-3-one derivatives induced apoptosis and elevated the level of P53 and Fas in A549 lung cancer cells.
He Q; Zhu X; Shi M; Zhao B; Zhao J; Zhang S; Miao J
Bioorg Med Chem; 2007 Jun; 15(11):3889-95. PubMed ID: 17395471
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.
Farrell GC; Larter CZ; Hou JY; Zhang RH; Yeh MM; Williams J; dela Pena A; Francisco R; Osvath SR; Brooling J; Teoh N; Sedger LM
J Gastroenterol Hepatol; 2009 Mar; 24(3):443-52. PubMed ID: 19226377
[TBL] [Abstract][Full Text] [Related]
39. Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).
Chomel JC; Sorel N; Bonnet ML; Bertrand A; Brizard F; Saulnier PJ; Roy L; Guilhot F; Turhan AG
Leuk Res; 2009 Apr; 33(4):551-5. PubMed ID: 18829107
[TBL] [Abstract][Full Text] [Related]
40. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Alessandro R; Fontana S; Giordano M; Corrado C; Colomba P; Flugy AM; Santoro A; Kohn EC; De Leo G
J Cell Physiol; 2008 Apr; 215(1):111-21. PubMed ID: 17924401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
